Abstract
The expansion of cancer therapeutics has paved the way for improved cancer-related outcomes. Cardiotoxicity from cancer therapy occurs in a small but significant subset of patients, is often poorly understood, and contributes to adverse outcomes at all stages of cancer treatment. Given the often-idiopathic occurrence of cardiotoxicity, novel strategies are needed for risk-stratification and early identification of cancer patients experiencing cardiotoxicity. Clinical and research tools extending from imaging to blood-based biomarkers and pluripotent stem cells are being explored as methods to study the cardiovascular impact of various cancer treatments. Here we provide an overview of tools currently available for evaluation of cardiotoxicity and highlight novel techniques in development aimed at understanding underlying pathophysiologic mechanisms.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 417-430 |
| Number of pages | 14 |
| Journal | Journal of Cardiovascular Translational Research |
| Volume | 13 |
| Issue number | 3 |
| DOIs | |
| State | Published - Jun 1 2020 |
| Externally published | Yes |
Keywords
- Biomarkers
- Cardiac CT
- Cardiac MRI
- Cardio-oncology
- Cardiotoxicity
- Nuclear imaging
ASJC Scopus subject areas
- Molecular Medicine
- Genetics
- Pharmaceutical Science
- Cardiology and Cardiovascular Medicine
- Genetics(clinical)